Overall survival and biomarker results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results